ORGANOGENESIS HOLDINGS INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ORGANOGENESIS HOLDINGS INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $130.00K, a 3150.00% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $25.00K, a 86.11% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $4.00K.
- ORGANOGENESIS HOLDINGS INC. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $180.00K.
- ORGANOGENESIS HOLDINGS INC. stock issued during period, value, stock options exercised for fiscal 2025 was $157.00K, a 87.41% decline from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.25M.
- ORGANOGENESIS HOLDINGS INC. stock issued during period, value, stock options exercised for fiscal 2022 was $2.07M.
- ORGANOGENESIS HOLDINGS INC. stock issued during period, value, stock options exercised for fiscal 2021 was -$2.20M.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $157.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $130.00K 10-Q · filed 2025-11-06 | |
| 2025-03-31 | $25.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $1.25M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $4.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $180.00K 10-Q · filed 2025-11-06 | |
| 2022-12-31 | $4.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.07M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$28.00K 10-Q · filed 2023-11-09 | -$2.15M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$1.75M 10-Q · filed 2023-08-09 | -$3.04M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$291.00K 10-Q · filed 2023-05-10 | -$1.50M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$2.20M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$910.00K 10-Q · filed 2022-11-09 | -$3.65M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$221.00K 10-Q · filed 2022-08-09 | -$3.06M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$984.00K 10-Q · filed 2022-05-10 | -$2.99M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$2.82M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$318.00K 10-Q · filed 2021-11-09 | -$1.39M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$152.00K 10-Q · filed 2021-08-09 | -$1.18M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$816.00K 10-Q · filed 2021-05-11 | -$1.08M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$269.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | -$109.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | -$54.00K 10-Q · filed 2020-08-10 | |
| 2018-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$119.00K 10-K · filed 2021-03-16 |
| 2018-09-30 | -$33.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$34.00K 10-Q · filed 2019-08-09 | |
| 2018-03-31 | -$44.00K 10-Q · filed 2019-08-09 | |
| 2017-12-31 | -$221.00K 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |